Why the study?
Does the thrombospondin-1 N700S polymorphism increase the risk of early myocardial infarction?
Does the thrombospondin-1 N700S polymorphism increase the risk of early myocardial infarction?
The TSP-1 N700S polymorphism is a genetic risk factor for early myocardial infarction, but this prothrombotic phenotype does not appear to be mediated by altered VWF multimer size.
N700S polymorphism was associated with early MI risk; leaves open non-VWF prothrombotic mechanisms.
The N700S polymorphism of thrombospondin-1 (TSP-1) has been identified as a potential genetic risk factor for myocardial infarction (MI). In a large case-control study of 1425 individuals who survived a myocardial infarction prior to age 45, the N700S polymorphism was a significant risk factor for myocardial infarction in both homozygous (odds ratio [OR] 1.9, 95% confidence interval [CI] 1.1-3.3, P = .01) and heterozygous carriers of the S700 allele (OR 1.4, 95% CI 1.1-3.3, P = .01). TSP-1 has been shown to reduce von Willebrand factor (VWF) multimer size, and the domain responsible for VWF-reducing activity has been localized to the calcium-binding C-terminal sequence. As the N700S polymorphism was previously shown to alter the function of this domain, we investigated whether the altered VWF-reducing activity of TSP-1 underlies the observed prothrombotic phenotype. The TSP1 N700S polymorphism did not influence VWF multimer size in patients homozygous for either allele nor was there a significant reduction of VWF multimer size following incubation with recombinant N700S fragments or platelet-derived TSP-1.
No takes yet. Share an insight, caveat, or question.
Jeffrey I. Zwicker (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: